159 related articles for article (PubMed ID: 20028259)
1. Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells.
Brar VS; Sharma RK; Murthy RK; Chalam KV
J Ocul Pharmacol Ther; 2009 Dec; 25(6):507-11. PubMed ID: 20028259
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells.
Spitzer MS; Wallenfels-Thilo B; Sierra A; Yoeruek E; Peters S; Henke-Fahle S; Bartz-Schmidt KU; Szurman P;
Br J Ophthalmol; 2006 Oct; 90(10):1316-21. PubMed ID: 16723358
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line.
Sharma RK; Chalam KV
Acta Ophthalmol; 2009 Sep; 87(6):618-22. PubMed ID: 19563375
[TBL] [Abstract][Full Text] [Related]
4. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
Spitzer MS; Yoeruek E; Sierra A; Wallenfels-Thilo B; Schraermeyer U; Spitzer B; Bartz-Schmidt KU; Szurman P
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1837-42. PubMed ID: 17347807
[TBL] [Abstract][Full Text] [Related]
5. Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage.
Thaler S; Fiedorowicz M; Choragiewicz TJ; Bolz S; Tura A; Henke-Fahle S; Yoeruek E; Zrenner E; Bartz-Schmidt KU; Ziemssen F; Schuettauf F
Acta Ophthalmol; 2010 Aug; 88(5):e170-6. PubMed ID: 20491691
[TBL] [Abstract][Full Text] [Related]
6. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.
Schnichels S; Hagemann U; Januschowski K; Hofmann J; Bartz-Schmidt KU; Szurman P; Spitzer MS; Aisenbrey S
Br J Ophthalmol; 2013 Jul; 97(7):917-23. PubMed ID: 23686000
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cytotoxic effects of bevacizumab on human corneal cells.
Chalam KV; Agarwal S; Brar VS; Murthy RK; Sharma RK
Cornea; 2009 Apr; 28(3):328-33. PubMed ID: 19387236
[TBL] [Abstract][Full Text] [Related]
8. Growth-related effects of oxidant-induced stress on cultured RPE and choroidal endothelial cells.
Eichler W; Reiche A; Yafai Y; Lange J; Wiedemann P
Exp Eye Res; 2008 Oct; 87(4):342-8. PubMed ID: 18640112
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells.
Luthra S; Narayanan R; Marques LE; Chwa M; Kim DW; Dong J; Seigel GM; Neekhra A; Gramajo AL; Brown DJ; Kenney MC; Kuppermann BD
Retina; 2006; 26(5):512-8. PubMed ID: 16770256
[TBL] [Abstract][Full Text] [Related]
10. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro.
Terasaki H; Sakamoto T; Shirasawa M; Yoshihara N; Otsuka H; Sonoda S; Hisatomi T; Ishibashi T
Retina; 2015 May; 35(5):1007-15. PubMed ID: 25627091
[TBL] [Abstract][Full Text] [Related]
11. Effect of anti-VEGF antibody on retinal ganglion cells in rats.
Iriyama A; Chen YN; Tamaki Y; Yanagi Y
Br J Ophthalmol; 2007 Sep; 91(9):1230-3. PubMed ID: 17475701
[TBL] [Abstract][Full Text] [Related]
12. Differential sensitivity of choroidal endothelial, retinal ganglion, and retinal pigment epithelial cells in vitro to proton radiation.
Balaiya S; Murthy RK; Malyapa R; Grover S; Chalam KV
Am J Ophthalmol; 2013 Sep; 156(3):444-453.e2. PubMed ID: 23769193
[TBL] [Abstract][Full Text] [Related]
13. Choroidal endothelial cells transmigrate across the retinal pigment epithelium but do not proliferate in response to soluble vascular endothelial growth factor.
Geisen P; McColm JR; Hartnett ME
Exp Eye Res; 2006 Apr; 82(4):608-19. PubMed ID: 16259980
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab modulates epithelial-to-mesenchymal transition in the retinal pigment epithelial cells via connective tissue growth factor up-regulation.
Chen CL; Liang CM; Chen YH; Tai MC; Lu DW; Chen JT
Acta Ophthalmol; 2012 Aug; 90(5):e389-98. PubMed ID: 22712616
[TBL] [Abstract][Full Text] [Related]
15. Effects of bevacizumab (Avastin) on retinal cells in organotypic culture.
Kaempf S; Johnen S; Salz AK; Weinberger A; Walter P; Thumann G
Invest Ophthalmol Vis Sci; 2008 Jul; 49(7):3164-71. PubMed ID: 18344448
[TBL] [Abstract][Full Text] [Related]
16. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells.
Peters S; Julien S; Heiduschka P; Grisanti S; Ziemssen F; Adler M; Schraermeyer U; Bartz-Schmidt KU
Br J Ophthalmol; 2007 Jun; 91(6):827-31. PubMed ID: 17179166
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.
Sheu SJ; Chao YM; Liu NC; Chan JY
Acta Ophthalmol; 2015 Dec; 93(8):e631-43. PubMed ID: 25975662
[TBL] [Abstract][Full Text] [Related]
18. Modulation of bevacizumab-induced toxicity for cultured human corneal fibroblasts.
Kim EK; Kang SW; Kim JY; Min K; Kim TI
Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):3922-31. PubMed ID: 23640039
[TBL] [Abstract][Full Text] [Related]
19. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
Saenz-de-Viteri M; Fernández-Robredo P; Hernández M; Bezunartea J; Reiter N; Recalde S; García-Layana A
Biochem Pharmacol; 2016 Mar; 103():129-39. PubMed ID: 26793998
[TBL] [Abstract][Full Text] [Related]
20. Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
Young M; Chui L; Fallah N; Or C; Merkur AB; Kirker AW; Albiani DA; Forooghian F
Retina; 2014 Jul; 34(7):1308-15. PubMed ID: 24451923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
